At Versa Biomedical, we continue to work to ensure that science advances in a more open, collaborative and accessible way.

That is why we are especially pleased to share that Versa Biomedical is now officially CIR-approved in France (agrément CIR). This accreditation allows French companies carrying out R&D projects (from early stages through to Phase IV) to benefit from the Crédit d’Impôt Recherche when working with us, reducing the net cost of eligible projects.

Beyond the fiscal framework, this recognition reinforces something we deeply believe in: enabling scientifically sound projects to move forward without unnecessary barriers, supported by rigorous and well-established preclinical models, such as our in vivo pig models and human cadaver studies.

We continue to support each project from scope definition through to study execution, helping assess CIR eligibility and providing scientific support throughout the entire process.

Because opening models also means opening opportunities. And because building possible futures requires making research more accessible, connected and viable.

Open models, open futures.